Treatment Sequencing Strategies in Lung Cancer

Daniel Humberto Pozza¹, Ramon Bezerra Andrade de Mello²

¹Department of Biomedicine, Faculty of Medicine and i3s, University of Porto, 4200-319 Porto, Portugal; ²Discipline of Medical Oncology, Post-graduation Program in Medicine, Nine of July University (UNINOVE), São Paulo, Brazil./Nine of July Hospital, São Paulo, Brazil

Abstract

Background and objective The advances in the lung cancer screening methods and therapeutics, together with awareness towards deleterious habits, such as smoking, is increasing the overall survival with better quality of life for the patients. However, lung cancer is still one of the most common and fatal neoplasm with a high incidence and consequently burden to public health worldwide. Thus, based on guidelines and recent phases II and III clinical trials studies, this manuscript summarizes the current treatment sequencing strategies in lung cancer.

Methods A comprehensive search of related articles was performed focused on phases II and III clinical trials studies.

Results The lung cancer management should take into consideration the tumor characteristics, histology, molecular pathology and be discussed in a multidisciplinary team. Lung cancer treatment options comprises surgery whenever possible, radiotherapy associate with/or chemotherapy and immunotherapy as monotherapy, or combined with chemotherapy and best palliative care.

Conclusions The screening predictability in more patients, smoking reduction, early diagnosis, better disease understanding and individualized, more effective and tolerable therapeutics are related to an increasing in overall survival and quality of life. In the near future improvement of personalized therapy in precision medicine is expected, enhancing new predictive biomarkers, optimal doses and optimal treatment sequencing as well as anti-cancer vaccines development.

Key words Lung neoplasms; Immunotherapy; Clinical trials; Targeted therapies; Pembrolizumab; Nivolumab; Atezolizumab; Necitumumab; Brigatinib

Competing interests The authors declare that they have no competing interests.

Introduction

Lung cancer is one of the most common neoplasm with a high mortality rate, representing a global burden to public health worldwide leading to disabilities and premature mortality since few patients will survive longer than 5 years. The malignant behavior and lack of cure leads to physical impairment and psychological distress with marked reduced quality of life, requiring a multidisciplinary and complex treatment[1-7].

The smoking reduction is responsible for the falling incidence of lung cancer, particularly in men. The early diagnosis, better disease understanding and more effective and tolerable therapeutics are related to an increasing in survival. The screening predictability in more patients, being diagnosed with earlier stages of the disease, are also increasing the candidates for surgery. The advances in histopathology, biomarkers and new genetics tools are helping to choose the most appropriate therapy[6-8,12]. The most predictive biomarkers are anaplastic lymphoma kinase (ALK) fusion oncogene, ROS1 gene rearrangements, mutant epidermal growth factor receptor (EGFR) kinases, human epidermal growth factor receptor-2 (HER2) and BRAF mutations, RET gene rearrangements, and high-level MET amplifications. Therapeutic advances, such as biomarker testing results should be expedited in order to prevent treatment delays, improving survival[8,13].

The recommended initial lung cancer workup should include computed tomography and magnetic resonance imaging and pathologic tests, to determine the tumor subtype with biomarkers, such as programmed death-ligand 1 (PD-L1) immunohistochemistry. EGFR, ALK, ROSI, BRAF, RET, METs or HER2 are also recommended in patients with non-squamous histology whenever possible and when next-generation sequencing is used[9].

Lung cancer approach and treatment should be based on patient status that includes medical history with comorbidities, physical examination, lungs capacity, cardiac risk, age, weight loss, performance status (PS) and preferences. The management should take into
consideration the tumor characteristics, histology, molecular pathology and be discussed together with a multidisciplinary team\cite{14-17}. Lung cancer is potentially curable when limited in stage by surgery. However, this is not possible for most cases and radiotherapy associate with/or chemotherapy are usually employed. For patients without an actionable driver mutation and when targeted therapies are not available, chemotherapy was the standard of care. Nowadays immunotherapy, mainly programmed death-1 (PD-1)/PD-L1 blockade immunotherapy, as monotherapy, or combined with chemotherapy is the standard of care because of survival benefits and less adverse events such as fatigue, nausea, diarrhea, decreased appetite and asthenia. Furthermore, anemia, alopecia, neutropenia, myalgia, and stomatitis are adverse events associated to chemotherapy only. On the other side, immunotherapy toxicity is more associated with hypothyroidism, hyperthyroidism, pneumonitis and rash, although they rarely occur\cite{1,18-22}.

Based on guidelines and recent phases II and III clinical trials studies, the objective of this review was to describe the current treatments of initial and advanced lung cancer through surgery, chemotherapy, immunotherapy, radiotherapy, and/or targeted therapy.

Methods

A comprehensive search of related articles was performed in PubMed.gov using Mesh Terms: "Lung Neoplasms"[Mesh] AND "Clinical Trial, Phase II" [Publication Type] AND "Clinical Trial, Phase III" [Publication Type] as well as ("Lung Neoplasms"[Mesh]) AND "Guideline" [Publication Type]. Additionally, some filters were selected including "Humans" in Species, "English" in Language and "Clinical trial" or "Review" in Article Type according to the Mesh Terms used. The manuscripts search was performed between April and June of 2021. The two readers carefully screened all articles obtained from the reported search initially based on titles and abstracts. Whenever no sufficient information in the title/abstract to allow decision making regarding inclusion or exclusion criteria, the article was evaluated only after full text was obtained and reviewed in order to make a final decision. Any disagreement between the two investigators were solved by consensus. Screening the reference lists of the selected articles complemented the search with additional manuscripts to be evaluated. The inclusion criteria comprised mainly up-to-date human clinical trials or reviews focused in guidelines based on human clinical trials. For the eligibility of the study, the full texts were accessed by extracting the data regarding the methods, participants, intervention and outcomes by both investigators, independently for discussion. The exclusion criteria included in vitro studies, outdated protocols, no full text in English or duplicated studies.

Results

In the first search, 381 articles were obtained and 244 articles were excluded after inclusion/exclusion criteria were employed. In the process of full texts assessments 9 manuscripts were also excluded by the two authors after reading abstracts and/or main texts. A total of 128 manuscripts were fully evaluated and 55 were exclude after reading and discussing the contents. In addition, after screening the reference lists of these 128 selected articles, 37 other manuscripts that did not appear in the first search, were also included. The two authors of the present review carefully evaluated, as many times as necessary, the 174 selected articles finally excluding 64 of them. Therefore, a total of 110 manuscripts were used in the present review. The flow diagram (Fig 1) describes the results of the manuscript search. Statistical analysis was performed with SPSS 27.0 and confirmed the high agreement between researches (Kappa=0.88).

Among the 110 included articles, 38 phases II or III clinical trials were selected, being 6 related to the small cell lung cancer (SCLC) treatment (Tab 1) and 24 to the non-small cell lung cancer (NSCLC) treatment (Tab 2). Additionally, 18 phases II or III clinical trials with focus on advanced NSCLC and molecular profile for gene mutations were also evaluated (Tab 3). These phases II or III clinical trials were organized in separate tables in comprehensive analysis section to facilitate comparisons.

Discussion

Lung cancer can be divided in two major histological types: SCLC\cite{23} and NSCLC\cite{23}. The NSCLC accounts more than 80% of all lung cancer and it comprises 2 major types: nonsquamous (e.g.: adenocarcinoma, large-cell carcinoma, and other cell types); and squamous cell carcinoma, being dived in stages 0 to IV\cite{4,24,25}. Some of the lung cancer main treatment options, according to the literature, are depicted in Fig 2.

The SCLC is a very chemosensitive tumor and therapeutics is usually based on combined chemoradiation for tumors confined to the chest and palliative chemotherapy for advanced or metastatic disease. Surgery is generally not recommended in the SCLC management due to the high risk of recurrence. For extensive SCLC, atezolizumab combined with cisplatin and etoposide is the only association that can improve the overall survival, although it is not approved by regulatory agencies worldwide\cite{26}. Cisplatin plus irinotecan
can be used in the subsequent treatment for patients with sensitive relapsed SCLC, because of better efficacy and longer overall survival than the single-agent topotecan. The association of amrubicin to cisplatin is a promising treatment option for Chinese patients. Alternatively, pembrolizumab or nivolumab plus ipilimumab can be employed in patients with a high tumor mutational burden, not previously treated with immunotherapy. Other promising targeted therapeutics includes talazoparib, veliparib and rovalpituzumab tesirine. Treatment through the combination of rilotumumab and ganitumab with platinum-based chemotherapy is also being studied for those patients with extensive stage SCLC. Selected studies of phases II or III clinical trials are summarized in Tab 1.

**Tab 1 Phases II or III clinical trials related to the SCLC treatment**

| Reference                        | Brief study methods                                                                 | Relevant key findings                                      |
|----------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------|
| Horn et al (2018)                | Phase III multinational trial: carboplatin and etoposide with either atezolizumab or placebo in SCLC without previously treatment | Atezolizumab+chemotherapy=significantly longer overall survival and progression-free survival |
| Goto et al (2016)                | Phase III trial: chemotherapy+cisplatin, etoposide, and irinotecan VS topotecan monotherapy as second-line chemotherapy in patients with sensitive relapsed SCLC in Japan | The proposed combination can be considered the standard second-line for sensitive relapsed SCLC |
| Satouchi et al (2014)            | Phase III trial: amrubicin+cisplatin (AP) vs irinotecan+cisplatin (IP) in chemotherapy-naive patients with extensive SCLC in Japan | AP is inferior to IP, being IP the standard treatment for extensive-stage SCLC |
| Sun et al (2016)                 | Phase III trial: amrubicin+cisplatin (AP) vs etoposide and cisplatin (EP) for previously untreated SCLC in China. | AP therapy demonstrated non-inferiority to EP therapy, prolonging survival for 1.5 months |
| Trafalis et al (2016)            | Phase II trial: irinotecan+bevacizumab in relapsed chemoresistant SCLC in Greece | Combination demonstrates promising efficacy and low toxicity compared to controls |
| Glisson et al (2017)             | Phases Ib and II multinational trials: rilotumumab or ganitumab or placebo+chemotherapy as first-line treatment in SCLC | Improved survival for rilotumumab. Rilotumumab or ganitumab + chemotherapy are tolerable, overall outcomes were not improved in patients with SCLC |

SCLC: small cell lung cancer; vs: versus; AP: amrubicin+cisplatin; IP: irinotecan+cisplatin; EP: etoposide and cisplatin.
### Tab 2 Phases II or III clinical trials related to the NSCLC treatment

| Reference | Study brief methods | Relevant key findings |
|-----------|---------------------|-----------------------|
| Paz-Ares et al (2018) | Phase III multinational trial: pembrolizumab vs placebo. Both groups with carboplatin+paclitaxel in metastatic, squamous NSCLC | Addition of pembrolizumab to chemotherapy resulted in significantly longer overall survival and progression-free survival than chemotherapy alone |
| Weiss et al (2016) | Phase II trial: pemetrexed, and bevacizumab for never or former/light smoking patients stage IIIB, IV non-squamous NSCLC in United States | Combination of the carboplatin, pemetrexed and bevacizumab demonstrated activity with acceptable toxicity |
| Ferry et al (2017) | Phase III trial: platinum agent and dose of cisplatin in relation to chemo-naïve stage IIIB/IV NSCLC patient outcomes in United Kingdom and Ireland | Gemcitabine+carboplatin is not inferior to cisplatin in terms of survival |
| Palussiere et al (2018) | Phase II/III trial: survival outcomes of percutaneous radiofrequency ablation (RFA) for patients with stage Ia NSCLC, ineligible for surgery in France | Carboplatin with more adverse events and cisplatin with worse survival |
| Camerini et al (2015) | Phase II trial: oral vinorelbine in chemotherapy-naive elderly (>70 years) PS 0-2 patients with stage IIIB to IV NSCLC in Italy | Safe in elderly patients with long-term disease stabilization coupled with an optimal patient compliance |
| Katsaounis et al (2015) | Phase II trial: metronomic vinorelbine in combination with cisplatin as first-line treatment in inoperable stage IIIB or stage IV NSCLC in Greece | The combination is active, although myelotoxic, therapeutic option in the first-line setting |
| Ikeda et al (2018) | Phase II trial: combination therapy of bevacizumab, cisplatin, and docetaxel, followed by bevacizumab as maintenance in chemotherapy-naïve with stages IIIA, IIIB and IV NSCLC in Japan | The combination therapy was highly effective, despite the high incidence of grade 3/4 neutropenia |
| Socinski et al (2018) | Phase III multinational trial: atezolizumab+bevacizumab+chemotherapy in metastatic non-squamous NSCLC without previously chemotherapy | The combination significantly improved progression-free survival and overall survival, regardless of PD-L1 expression |
| Hellmann et al (2018) | Phase III multinational trial: nivolumab+ipilimumab vs chemotherapy in stage IV or recurrent NSCLC | Progression-free survival significantly longer for combination than chemotherapy, irrespective of PD-L1 expression level |
| Reck et al (2016) | Phase III multinational trial: pembrolizumab vs platinum-based chemotherapy in untreated stage IV NSCLC, with PD-L1 expression on at least 50% of tumor cells | Pembrolizumab allowed significantly longer progression-free and overall survival and with fewer adverse events |
| Gandhi et al (2018) | Phase III multinational trial: pemetrexed and a platinum-based drug plus either pembrolizumab or placebo in metastatic nonsquamous NSCLC without previous treatment for metastatic disease | Pembrolizumab+standard chemotherapy resulted in significantly longer overall survival and progression-free survival than chemotherapy alone |
| Sandler et al (2000) | Phase III trial: gemcitabine+cisplatin vs cisplatin alone in chemotherapy-naïve patients with unresectable stage IIIA, IIIB, or IV NSCLC in United States. | Gemcitabine+cisplatin is superior in terms of response rate, time to disease progression, and overall survival |
| Park et al (2007) | Phase III trial: additional four or two more cycles of third-generation, platinum-doublet treatment for stages IIIB to IV NSCLC resistant to chemotherapy in United States | Similar overall survival with four or six cycles of chemotherapy with favourable time to progression for six cycles |
| Pujol et al (2014) | Phase III multinational trial: pemetrexed maintenance vs placebo in advanced non-squamous NSCLC | Low incidence of low-grade toxicities with long-term pemetrexed exposure without compromising quality of life |
| Paz-Ares et al (2013) | Phase III multinational trial: pemetrexed continuation maintenance vs placebo in advanced non-squamous NSCLC | Pemetrexed is well-tolerated and offers superior survival, also an efficacious treatment for patients who did not progress during pemetrexed-cisplatin induction therapy |
| Lee et al (2015) | Phase II multinational trial: pemetrexed+dexamethasone, folic acid, and vitamin B12+erlotinib vs erlotinib vs pemetrexed in EA and non-EA never-smoker patients and patients with advanced or metastatic non-squamous NSCLC | Better progression-free survival for pemetrexed-erlotinib in EA patients |
| van Kruisdijk et al (2016) | Phase II multinational trial: pemetrexed+carboplatin single-agent pemetrexed in the second-line setting of stages IIIB and IV NSCLC | Combination benefited most women, stage IV, high body mass index and/or adenocarcinoma. Individualized treatment can improve clinical outcome |
| Ellis et al (2015) | Phase II multinational trial: volasertib monotherapy or pemetrexed vs pemetrexed monotherapy in recurrent, advanced, or metastatic NSCLC after previous platinum-based chemotherapy | The combination did not increase toxicity but also did not improve efficacy compared with single-agent pemetrexed |
| Paz-Ares et al (2017) | Phase III multinational trial: ramucirumab+docetaxel vs docetaxel alone in squamous or non-squamous stage IV NSCLC | Favourable overall survival and manageable safety for combination |
| Reck et al (2017) | Phase III multinational trial: docetaxel+ramucirumab vs placebo in refractory patients stage IV NSCLC | Combination is an appropriate treatment option even in this difficult-to-treat population |
| Rittmeyer et al (2017) | Phase III multinational trial: atezolizumab+docetaxel in previously treated squamous or non-squamous NSCLC | Atezolizumab treatment resulted in a relevant improvement of overall survival, regardless of PD-L1 expression or histology, with a favourable safety profile |
| Borghaei et al (2015) | Phase III multinational trial: nivolumab vs docetaxel in previously treated squamous or non-squamous NSCLC | Overall survival longer with nivolumab than with docetaxel for advanced previously treated non-squamous NSCLC |
| Herbst et al (2016) | Phase II/III multinational trial: pembrolizumab vs docetaxel in previously treated PD-L1-positive, advanced NSCLC | Pembrolizumab prolongs overall survival and has a favourable benefit-to-risk profile in previously treated patients |
| Neal et al (2016) | Phase II trial: erlotinib, cabozantinib, or erlotinib and cabozantinib in advanced non-squamous NSCLC in United States | Cabozantinib alone or erlotinib has clinically meaningful, superior efficacy over erlotinib alone, with additional generally manageable toxicity |

NSCLC: non-small cell lung cancer; vs: versus; RFA: radiofrequency ablation; PS: performance status; PD-L1: programmed death-ligand 1; EA: East Asian.
### Tab 3 Phases II or III clinical trials with focus on advanced NSCLC when molecular profile for gene mutations are positive

| Reference | Brief study methods | Relevant key findings |
|-----------|---------------------|-----------------------|
| Paz-Ares et al (2017) | Phase IIb multinational trial: afatinib vs gefitinib in treatment-naive patients with stage IIIb/IV NSCLC and a common EGFR mutation | Progression-free survival, time-to-treatment failure and objective response rate were significantly improved with afatinib with no significant difference in overall survival |
| Soria et al (2018) | Phase III multinational trial: osimertinib vs gefitinib or erlotinib in previously untreated EGFR mutation-positive in advanced or metastatic NSCLC | Osimertinib showed superior efficacy with a similar safety profile and lower rates of serious adverse events |
| Wu et al (2017) | Phase III multinational trial: oral dacomitinib vs oral gefitinib in EGFR-mutation-positive newly diagnosed advanced NSCLC | Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment |
| Reungwetwattana et al (2018) | Phase III multinational trial: osimertinib vs standard EGFR tyrosine kinase inhibitors in locally advanced or metastatic EGFR-mutated NSCLC | Osimertinib has CNS efficacy and reduced risk in patients with untreated EGFR-mutated NSCLC |
| Seto et al (2014) | Phase II trial: erlotinib+bevacizumab vs erlotinib alone in stage IIIb/IV or recurrent non-squamous NSCLC with activating EGFR mutation-positive disease in Japan | Combination presented better median progression-free survival and serious adverse events occurred at a similar frequency in both groups |
| Barata et al (2016) | Phase II trial: erlotinib in metastatic NSCLC with activating mutations in the tyrosine kinase (TK) domain of the EGFR in Portugal | Similar results compared with other clinical trials in Caucasian patients |
| Gridelli et al (2016) | Phase III trial: erlotinib+bevacizumab vs erlotinib in advanced NSCLC harboring activating EGFR mutations in Italy | The combination seems to be the best first-line treatment |
| Janne et al (2014) | Phase II multinational trial: dacomitinib as initial systemic therapy in stage IIIb/IV NSCLC adenocarcinoma EGFR-mutant | Only 6% of patients discontinued dacomitinib due to adverse event. Dacomitinib was associated with clinically meaningful improvements in multiple disease-related symptoms early on, and these improvements were maintained over time |
| Yoshimura et al (2015) | Phase II trial: gefitinib and pemetrexed as first-line chemotherapy in EGFR-mutated NSCLC in Japan | Combination showed a high overall response rate, long median progression-free survival and acceptable toxicity |
| Shaw et al (2013) | Phase III trial: crizotinib vs intravenous pemetrexed or docetaxel in locally advanced or metastatic ALK-positive lung cancer in United States | Crizotinib is superior including progression-free survival, response rate, symptoms of lung cancer and global quality of life |
| Solomon et al (2018) | Phase III multinational trial: crizotinib vs pemetrexed+cisplatin or carboplatin as first-line treatment in advanced ALK-positive non-squamous NSCLC | Crizotinib allowed longest overall survival |
| Soria et al (2017) | Phase III multinational trial: ceritinib vs platinum-based chemotherapy in stage IIb/IV ALK-rearranged non-squamous NSCLC | Ceritinib showed a marked improvement in progression-free survival |
| Novello et al (2018) | Phase III multinational trial: alectinib vs platinum-based chemotherapy in advanced/metastatic ALK-positive NSCLC patients previously treated with platinum-based doublet chemotherapy and crizotinib | Alectinib significantly improved systemic and CNS efficacy and grade >3 adverse events were more common with chemotherapy |
| Planchard et al (2017) | Phase II multinational trial: dabrafenib+trametinib in BRAF(V600E)-mutant metastatic NSCLC | Combination presented a clinically meaningful antitumour activity and a manageable safety profile |
| Hyman et al (2015) | Phase II multinational trial: vemurafenib in BRAF V600E mutation-positive nonmelanoma cancers including NSCLC | Vemurafenib presented modest antitumor activity |
| Soria et al (2017) | Phase II multinational trial: docetaxel+sorafenib vs placebo in KRAS-mutant advanced NSCLC | Combination showed no clinical benefit compared with docetaxel alone |
| Hirano et al (2017) | Phase II trial: erlotinib low dose as maintenance treatment after platinum doublet chemotherapy in NSCLC harboring EGFR mutation in Japan | Study was stopped early due to poor accrual with the suggestion that maintenance therapy with low-dose erlotinib might be useful and tolerable |
| Paz-Ares et al (2015) | Phase III multinational trial: afatinib or matching placebo in advanced relapsed/refractory, wild-type or mutated KRAS NSCLC | Third-/fourth-line sorafenib therapy increased progression-free survival but not overall survival |

**ALK: anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; KRAS: Kirsten rat sarcoma; CNS: central nervous system.**
with comorbidities and decreased pulmonary function.
- If, after first surgery, there are still positive margins a new resection followed by radiotherapy, whenever possible, should be performed [15,33-36].

For severe illness patients, medically inoperable, the radiotherapy such as stereotactic body radiation therapy (SBRT) or radiofrequency ablation (RFA) may be the first treatment option. However, when tumor is completely resected, postoperative radiotherapy is not routinely recommended [15,34,37-39]. Chemotherapy can be used in the preoperative period with positive results since it can reduce the tumor size. Furthermore, the overall survival, time to distant recurrence, and recurrence free can be significantly improved [23].

Treatment algorithm for stage II NSCLC
Stage II NSCLC patients are treated in the same basis of the stage I, but again, more invasively if the health of the patient allows respiratory resection surgery including lymph nodes. Surgery, whenever possible, is still the best choice to manage stage II. The extension of the tumor will influence in the surgical technique:
- For healthy patients, stage II, lobectomy or anatomic pulmonary resection together with mediastinal lymph node dissection is recommended [15,34].
- If, after first surgery, there are still positive margins, a new resection followed by radiotherapy, whenever possible, should be performed. The adjuvant treatment with four cycles of cisplatin-based chemotherapy can increase the overall survival for completely resected tumors [15,33,34]. The reduction of the cisplatin can improve the quality of life, however it is not recommended because of the worsening in survival [38]. Higher risk patients should be treated as escribed in stage I.

Due to the limited benefits, chemotherapy and radiotherapy are generally not recommended. For severe illness patients, with node negative tumors ≤5 cm and those older than 75 years, the stereotactic ablative radiotherapy may be an option. This treatment choice should be discussed with patients since it can decrease survival [34,40,41].

Treatment algorithm for stages IIIa IIIb and IIIc NSCLC
Since there are no specific guidelines to determine to what extent lung tumors should be considered resectable or unresectable disease, an experienced multidisciplinary team is required in order to plan the treatment sequence for the heterogeneous and complex stage III NSCLC. Patients should undergo an accurate imaging diagnostic and receive brain imaging for initial staging. For presumably resectable stage IIIa, induction therapy (radiation/chemotherapy) followed by surgery, according to the extension of the tumor and the patient’s health, might be better than surgery alone.
If the tumor is surgically removed the following therapy will probably include 4 cycles of adjuvant cisplatin-based chemotherapy with subsequently radiation to improve overall survival\(^\text{[15,33,34,42-44]}\).

If, after first surgery, there are still positive margins a new resection followed by radiotherapy, whenever possible, should be performed. The adjuvant treatment with cisplatin-based chemotherapy can increase the overall survival for completely resected tumors\(^\text{[15,33,34]}\).

Stages IIIb, IIIc and some IIIa (multiple nodal involvement) are usually unresectables, being not possible to completely remove the tumors only by surgery. The more invasive procedure will also be conditioned by the health status. For medically fit patients the concurrent chemoradiotherapy with cisplatin-based chemotherapy, usually with etoposide or vinorelbine, is the first choice. Metronomic oral vinorelbine, although myelotoxic, promotes a safe long-term disease stabilization, being well-tolerated in elderly patients. The recommended radiotherapy is 60 Gy-66 Gy in 30-33 fractions over 6-7 weeks. When concurrent treatment is not possible, sequential chemotherapy followed by definitive radiotherapy is indicated. Durvalumab is an option for stage III NSCLC with PD-L1 expression equal or superior to 1%, after achieving disease control with platinum-based chemoradiation\(^\text{[15,33,34,45,46]}\). When patients are unsuitable for curative radiotherapy, the therapy should be based on stage IV treatment as described in the next section\(^\text{[47]}\).

**Treatment algorithm for stage IV NSCLC**

The widespread metastasis turns the stage IV NSCLC very difficult to be managed. The first treatment choice will take many aspects in consideration that must be discussed in a multidisciplinary team, in order to choose the best individualized option. In general, systemic therapy (including targeted therapy and immunotherapy), clinical trials, and/or palliative care will be the treatment choice, according to the extension of the disease and the patient health status\(^\text{[4]}\).

Tumor mutational burden is a promise biomarker for immune checkpoint blockade efficacy, mainly in patients with PD-L1 negative. The immunotherapy treatment is more responsive when PD-L1 tumor levels are high\(^\text{[48]}\). When PD-L1 expression is \(\geq\)50% pembrolizumab can be a first option as monotherapy. Pembrolizumab plus chemotherapy is the standard of care, irrespective of PD-L1 expression. Bevacizumab plus chemotherapy was the standard of care before immunotherapy, although it is contraindicated for squamous-cell tumors, bleeding high risk patients, or when the tumor is near large blood vessels. Bevacizumab plus chemotherapy combined with atezolizumab also improves outcomes as first-line treatment for nonsquamous metastatic NSCLC patients\(^\text{[3,4,9,49]}\). Nivolumab plus ipilimumab can improve outcomes and should be considered for first-line treatment\(^\text{[50]}\).

Excision repair cross-complementation group 1 (ERCC1) low expression from IIIb to IV NSCLC is related to favorable treatment with cisplatin-based chemotherapy. Furthermore, ERCC1-positive tumors presents benefits in progression-free survival when treated with erlotinib and bevacizumab\(^\text{[51]}\).

Treatment algorithms for stage IV NSCLC when molecular tests for gene mutations are negative:

If PS 0-1 and PD-L1 \(\geq\)50% of tumor cells: pembrolizumab monotherapy is the first treatment option, irrespective of histology, since this drug presents better overall survival with fewer adverse events and lower risk of death than platinum-based chemotherapy\(^\text{[4,8,9,18,52-55]}\). Combination of immunotherapy plus platinum-based chemotherapy may be considered due its increase in response rate\(^\text{[8,9,16,49,56]}\).

If PS 0-1 and PD-L1 \(<\)50% or unknown: the standard of care is pembrolizumab plus platinum-based chemotherapy regardless of tumor histology, followed by pembrolizumab maintenance therapy (pembrolizumab plus pemetrexed for non-squamous tumors)\(^\text{[8,34,38,57]}\). Alternatively, and irrespective of PD-L1 expression, nivolumab associated with ipilimumab can be used in patients who do not tolerate chemotherapy or wish to preserve chemotherapy as a future treatment option\(^\text{[8,14,58]}\). Atezolizumab plus bevacizumab combined with platinum-based chemotherapy is also an acceptable option\(^\text{[49]}\).

Squamous cell carcinoma (SCC): Four cycles of platinum-based doublets (up to 6 cycles in selected cases) with the addition of a third-generation cytotoxic agent (gemcitabine, vinorelbine, taxanes) therapies is recommended\(^\text{[34,39,60]}\). Atezolizumab or pembrolizumab and carboplatin plus paclitaxel or nab-paclitaxel/carboplatin (better overall response rate and tolerability than sb-paclitaxel/carboplatin) presents better results than only chemotherapy, regardless of PD-L1 expression\(^\text{[8,34,49,61]}\).

Non-squamous-cell carcinoma (non-SCC): Platinum-based doublet with a third-generation agent is recommended. The addition of bevacizumab, pembrolizumab or atezolizumab in the treatment of selected patients can increase the overall survival\(^\text{[9,34,49,56,60,62]}\). After chemotherapy, pemetrexed and bevacizumab/atezolizumab or pemetrexed and pembrolizumab can be used as long-term in the maintenance of stable disease, with no important safety concerns, being well-tolerated and increasing overall survival for patients with good performance status, after no progression with pemetrexed-cisplatin\(^\text{[63-65]}\). Nivolumab plus ipilimumab can improve outcomes compared to chemotherapy for high tumor mutation burden patients,
although it was not approved by regulatory agencies worldwide\cite{14}. Selected studies of phases II or III clinical trials are summarized in Tab 2.

Treatment algorithms for stage IV NSCC when molecular tests for gene mutations are positive:

The treatment standard of care should include tumor molecular profiling. The most predictive biomarkers are ALK, ROS1 gene rearrangements, sensitizing EGFR mutations, HER2 and BRAF V600E, Kirsten rat sarcoma (KRAS) mutations, RET gene rearrangements, and high-level MET amplifications\cite{4,66,67}. For these genetic alterations, molecular profiling with targeted therapies are considered the first treatment choice. However, there are no personalized targeted therapy approved for some of these mutations and the first treatment choice is still chemotherapy\cite{66,68}.

EGFR pathway is present in most of NSCLC and leads to the continuous increase of the tumor through angiogenesis, invasion, metastasis and inhibition of apoptosis. Thus, when the mutation is positive, the therapeutics may intent to block the EGFR\cite{1,69}. For mutations in the EGFR discovered prior to first-line chemotherapy, the treatment can be performed by using erlotinib, gefitinib, afatinib, osimertinib or dacomitinib. If the mutation is discovered during first-line chemotherapy, this initial treatment and maintenance therapy should be finished. Alternatively, chemotherapy can be substituted by erlotinib, afatinib or gefitinib. Furthermore, when compared to chemotherapy, this therapeutic allow a better quality of life. When comparing these drugs, osimertinib and dacomitinib has shown better overall survival with less toxicity. The overall survival can also be slight improved by the combinations of bevacizumab and erlotinib or of pemetrexed-carboplatin and gefitinib. In addition, osimertinib has a good progression-free survival among patients with central nervous system (CNS) metastasis\cite{4,14,34,70-82}.

If the positive gene is the ALK or ROSI, the first treatment inhibitors can be crizotinib (unique option for patients with ROSI mutation), ceritinib, alectinib or brigatinib, presenting better results than chemotherapy. Crizotinib presents few side effects and a very high response in patients with positive ALK advanced NSCLC, including those with brain metastases. However, due to possible adverse effects, close monitoring of liver function is recommended when using crizotinib. First-line alectinib improved outcomes compared to first-line crizotinib. Alternatively, if these drugs are not tolerated or ineffective, brigatinib or lorlatinib can be used in trials, since they are not approved by regulatory agencies worldwide\cite{1,4,14,16,34,83-89}.

When the changes affect the BRAF gene (V600E), the treatment can be the combination of dabrafenib and trametinib. If BRAF/MEK inhibitor where used in first-line treatment, platinum-based chemotherapy can be used in the subsequent therapy\cite{14,66,69,90}.

The most common lung cancer oncogenic alteration mutation is in the KRAS, being related to smoking and poor prognosis in NSCLC. There is not any targeted-therapy for KRAS-mutated patients\cite{4,66,68,92}. Selected studies of phases II or III clinical trials are summarized in Tab 3.

**Additional management**

Smoking cessation must be advised in any stage of the disease since it can improve the outcomes of the treatment because of the interaction with the employed drugs. The preferred approach includes behavior techniques along with pharmacotherapy. Furthermore, stop smoking improves quality of life by reducing the "guilty" feeling. A follow-up is also advised to close observe the evolution of the treatment, as well as, to identify complications, health and mental status. It is also of paramount importance to evaluate the palliative care timing, mainly for patients with advanced disease\cite{14-16,34}.

**Subsequent therapy**

When lung cancer does not stop developing during therapeutics, or recurs after first treatment, the subsequent management will be based on tumor and patient characteristics, as well as, modalities of previous approaches. In subsequent therapy, all molecular tests not performed before are recommended. If lung cancer continues to develop during chemotherapy, as the first treatment, subsequent therapy most often consists of a single drug such as pemetrexed or docetaxel\cite{4,34,93,94}. However, the association of docetaxel with nintedanib or ramucirumab presents better efficacy with manageable toxicity. On the other hand, the association of docetaxel plus a targeted drug such as selumetinib presents no benefits and should be avoided. Ramucirumab presents contra-indications due to the high risk of uncontrolled hypertension with severe hemorrhage, gastrointestinal perforation, bleeding or fistula. Thus, potential risks and benefits must be weighted before choosing this modality of treatment\cite{4,95-99}. The treatment with immunotherapeutic agents are justified in subsequent therapy because of the improvement in the overall survival, longer duration of response and less toxicity when compared with cytotoxic chemotherapy\cite{16,34,93}.

For metastatic non-SCC and SCC with no prior immunotherapy, single-agent pembrolizumab is a good option, with manageable side effects and prolonged overall survival in PD-L1-positive previously treated patients. Nivolumab or atezolizumab are recommended regardless of PD-L1 expression in order to improve overall survival with a favorable safety profile over docetaxel\cite{4,16,34,49,99-102}.

In
addition, anti-PD-1/PD-L1 antibodies treatment presents less toxicity (most common events being hypothyroidism, hyperthyroidism, skin rash, pneumonitis, and hepatitis) and better overall survival, progression free survival and overall response rate than docetaxel, mainly for higher levels of PD-L1 expression, and even when PD-L1 expression is \(<1\%\)\(\textsuperscript{[4,12,103]}\).

Additionally, osimertinib is recommended in patients with metastatic EGFR T790M-positive NSCLC that has progressed on erlotinib, gefitinib, or afatinib therapy\(\textsuperscript{[4,104-106]}\). The combination of cabozantinib plus erlotinib for second or third-line treatments presents better efficacy, with manageable additional toxicity, than monotherapy with erlotinib for EGFR wild-type NSCLC patients\(\textsuperscript{[107]}\). Monotherapy with sorafenib, despite increasing progression-free survival did no improve overall survival when used as a third-/fourth-line therapy\(\textsuperscript{[108]}\). Finally, new predictive biomarkers are expected to be developed in order to improve treatment individualization allowing the greatest benefit\(\textsuperscript{[54,68,109,110]}\).

**Clinical points**

In summary, SCLC therapeutics is usually based on chemoradiation, immunotherapy palliative chemotherapy for advanced or metastatic disease and surgery is generally not recommended. Extensive SCLC can be managed with immunotherapy associated or not with chemotherapy.

Except for stage 0, that is considered “in situ” and completely surgically removed, the NSCLC treatment is complex. Stage I NSCLC treatment is usually surgical and the extension of the tumor will influence in the surgical technique and the complementary radiotherapy. Preoperative chemoradiation has potential to reduce the tumor size. Stage II patients are treated more invasively in the same basis of the stage I. For stage III, if the tumor is surgically removed the following therapy will probably include chemotherapy with subsequently radiotherapy. When unresectable, chemoradiation with chemotherapy is the first choice. Immunotherapy associated or after chemotherapy can be an option. Stage IV represents a challenge and in general, systemic therapy, clinical trials, and/or palliative care will be the treatment choice, according to the histology, molecular tests for gene mutation, extension of the disease and the patient health status.

**Conclusions**

Up to now, despite the improvement in the overall survival, longer duration of response and toxicity reduction, there are still many gaps in the NSCLC treatment strategy algorithm, including the drug’s optimal doses and the optimal sequencing of immunotherapy and chemotherapy, when use associations, the role of vaccines, ideal duration of treatment, most appropriate approach to elderly and patients with poor performance status, and patients that eventually acquire resistance even after a personalized therapy. In addition, due to the burden of increasing costs, the benefits of some associations of target therapies and immunotherapy are questionable. In this context, new predictive biomarkers are expected to be developed in order to improve treatment individualization allowing the greatest benefit.

**Author contributions**

De Mello RA and Pozza DH designed the study and were responsible for articles selection, respective data collection and evaluation. Pozza DH wrote the manuscript draft and performed the statistical analysis. De Mello RA supervised the research, provided suggestions for the improvement of the study and finalized the manuscript. All the authors had access to the data. All authors read and approved the final manuscript as submitted.

**References**

1. Agustoni F, Suda K, Yu H, et al. EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. Cancer Treat Rev, 2019, 72: 15-27. doi: 10.1016/j.ctrv.2018.08.002
2. Cheng TY, Cramb SM, Baade PD, et al. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol, 2016, 11(10): 1653-1671. doi: 10.1016/j.jtho.2016.05.021
3. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med, 2018, 379(21): 2040-2051. doi: 10.1056/NEJMoa1810865
4. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2017, 15(4): 504-535. doi: 10.6004/jnccn.2017.0050
5. Frenkel M, Slater R, Sapire K, et al. Complementary and Integrative Medicine in Lung Cancer: Questions and Challenges. J Altern Complement Med, 2018, 24(9-10): 862-871. doi: 10.1089/acm.2018.0175
6. Gouvinhas C, De Mello RA, Oliveira D, et al. Lung cancer: a brief review of epidemiology and screening. Future Oncol, 2018, 14(6): 567-575. doi: 10.2217/fon-2017-0486
7. Sun M, Zheng X, Meng Q, et al. Interleukin-35 Expression in Non-Small Cell Lung Cancer is Associated with Tumor Progression. Cell Physiol Biochem, 2018, 51(4): 1839-1851. doi: 10.1159/000495706
8. Johnson M, Pennell NA, Borghaei H. “My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer. What Now?” Diagnosis and Initial Treatment Options for Newly Diagnosed Patients
With Advanced NSCLC. Am Soc Clin Oncol Educ Book, 2018(38): 696-707. doi: 10.1200/EDBK_201231

9 Gamerith G, Kocher F, Rudzik J, et al. ASCO 2018 NSCLC highlights-combination therapy is key. Memo, 2018, 11(4): 266-271. doi: 10.1007/s12554-018-0444-7

10 Amelio I, Mancini M, Petрова V, et al. p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc Natl Acad Sci U S A, 2018, 115(46): E10869-E10878. doi: 10.1073/pnas.1808314115

11 De Mello RA, Aguiri PN, Tadokoro H, et al. MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway. J Thorac Dis, 2018, 10(Suppl 17): S2076-S2078. doi: 10.21037/jtd.2018.04.122

12 Castro D, Moreira M, Guveia AM, et al. MicroRNAs in lung cancer. Oncotarget, 2017, 8(46): 81679-81685. doi: 10.18632/oncotarget.20955

13 Lim C, Tsoa MS, Le LW, et al. Biomarker testing and time to treatment decision in patients with advanced non-small cell lung cancer. Ann Oncol, 2015, 26(7): 1415-1421. doi: 10.1093/annonc/mdv208

14 Planchar D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2018, 29(Supplement 4): iv192-iv237. doi: 10.1093/annonc/mdy275

15 Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2017, 28(Supplement 4): iv1-iv21. doi: 10.1093/annonc/mdy275

16 Wu YL, Planchar D, Lu S, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol, 2018. doi: 10.1093/annonc/mdy554

17 Svaton M, Zemanova M, Skrickova J, et al. Chronic Inflammation as a Potential Predictive Factor of Nivolubumab Therapy in Non-Small Cell Lung Cancer. Anticancer Res, 2018, 38(12): 6771-6782. doi: 10.21873/anticancer.13048

18 Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Medicine (Baltimore), 2018, 97(33): e11936. doi: 10.1097/MD.0000000000011936

19 Thureau S, Dubray B, Modzelewski R, et al. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer. Radiat Oncol, 2018, 13(1): 208. doi: 10.1186/s13041-018-1147-2

20 Fujimoto D, Yamashita D, Fukuoka J, et al. Comparison of PD-1/L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDX and SP263. Anticancer Res, 2018, 38(12): 6891-6895. doi: 10.21873/anticancer.13065

21 Weiss JM, Villaruz LC, O’Brien J, et al. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer. Clin Lung Cancer, 2016, 17(2): 128-132. doi: 10.1016/j.cllc.2015.12.006

22 Zimmermann S, Peters S, OwinoKoko T, et al. Immune Checkpoint Inhibitors in the Management of Lung Cancer. Am Soc Clin Oncol Educ Book, 2018(38): 682-695. doi: 10.1200/EDBK_201319

23 Group NM-A-C. Preoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet, 2014, 383(9928): 1561-1571. doi: 10.1016/S0140-6736(13)62159-5

24 Rodriguez-Canales J, Parra-Cuestas E, Wistuba, II. Diagnosis and Molecular Classification of Lung Cancer. Cancer Treat Res, 2016, 170: 25-46. doi: 10.1007/978-3-319-40389-2_2

25 Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol, 2015, 10(9): 1243-1260. doi: 10.1097/JTO.0000000000000630

26 Horn L, Mansfield AS, Szcesna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med, 2018, 379(23): 2220-2229. doi: 10.1056/NEJMoa1809064

27 Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCGO0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2016, 17(8): 1147-1157. doi: 10.1016/S1470-2045(16)30104-8

28 Hansen HH. Management of small-cell cancer of the lung. Lancet, 1992, 339(8797): 846-849.

29 Satouchi M, Kotani Y, Shibata T, et al. Phase III study comparing amrubcin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCGO 0509. J Clin Oncol, 2014, 32(12): 1262-1268. doi: 10.1200/JCO.2013.53.5153

30 Sun Y, Cheng Y, Hao X, et al. Randomized phase III trial of amrubcin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer, 2016, 16: 265. doi: 10.1186/s12885-016-2301-6

31 Trafalas DT, Aliferis C, Statopoulos GP, et al. Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer. Cancer Chemother Pharmacol, 2016, 77(4): 711-722. doi: 10.1007/s00280-016-2983-0

32 Glisson B, Besse B, Dols MC, et al. A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer. Clin Lung Cancer, 2017, 18(6): 615-625.e618. doi: 10.1016/j.jclincr.2017.05.007

33 El-Sherif A, Gooding WE, Santos R, et al. Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg, 2006, 82(2): 408-415; discussion 415-416. doi: 10.1016/j.athoracsur.2006.02.029

34 Majem M, Juam O, Insu A, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol, 2019, 21(1): 3-17. doi: 10.1007/s12094-018-1978-1

35 Berfield KS, Wood DE. Sublobar resection for stage IA non-small cell lung cancer. J Thorac Dis, 2017, 9(Suppl 3): S208-S210. doi: 10.21037/jtd.2017.03.135

36 Xue Y, Wang YY, Zhang K, et al. A Study of Complete Video-Assisted Thoracoscopic Surgery Lobectomy in Treatment of Elderly Patients with Non-Small Cell Lung Cancer: Curative Effect and Impact on Clinical Prognosis. Cell Biochem Biophys, 2015, 73(2): 399-404. doi: 10.1007/
37 Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol, 2018, 36(9): 911-919. doi: 10.1200/JCO.2017.76.7293

38 Ferry D, Billingham L, Jarrett H, et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer, 2017, 83: 302-312. doi: 10.1016/s0959-8049(17)30137-1

39 Palussiere J, Chomy F, Savina M, et al. Radiofrequency ablation of stage Ia non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial. J Cardiothorac Surg, 2018, 13(1): 91. doi: 10.1186/s13018-018-0773-y

40 Group PM-tA. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database Syst Rev, 2000(2): CD002142. doi: 10.1002/14651858.CD002142

41 Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol, 2017, 7(5): 295-301. doi: 10.1016/j.prro.2017.04.014

42 Pigon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 2008, 26(21): 3552-3559. doi: 10.1200/JCO.2007.13.9030

43 Chen MY, Hu X, Xu YJ, et al. The impact of prophylactic cranial irradiation for post-operative patients with limited stage small cell lung cancer. Medicine (Baltimore), 2018, 97(44): e13029. doi: 10.1097/MD.0000000000013029

44 Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol, 2017, 8(1): 1-20. doi: 10.5306/wjco.v8.i1.1

45 Camerini A, Puccetti C, Donati S, et al. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer, 2015, 15: 359. doi: 10.1186/s12885-015-1534-2

46 Katsanos P, Kotsakis A, Agelaki S, et al. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemother Pharmacol, 2015, 75(4): 821-827. doi: 10.1007/s00280-015-2707-x

47 Ikefuna S, Kato T, Ogora T, et al. Phase II study of bevucizumab, cisplatin, and docetaxel plus maintenance bevucizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)0166. BMC Cancer, 2018, 18(1): 241. doi: 10.1186/s12885-018-4150-y

48 Aguilar PN, Jr., Santoro IL, Tadokoro H, et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy, 2016, 8(4): 479-488. doi: 10.2217/imt-2015-0002

49 Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med, 2018, 378(24): 2288-2301. doi: 10.1056/NEJMoa176948

50 Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med, 2018, 378(22): 2093-2104. doi: 10.1056/NEJMoa1801946

51 Villalobos M, Czapiewski P, Reimnuth N, et al. ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIIB/IV non-squamous non-small cell lung cancer. Med Oncol, 2018, 35(7): 106. doi: 10.1007/s12032-018-1169-5

52 Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 2016, 375(19): 1823-1833. doi: 10.1056/NEJMoa1601774

53 Pai-Scherf L, Blumenthal GM, Li H, et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist, 2017, 22(11): 1392-1399. doi: 10.1634/theoncologist.2017-0078

54 Russo A, Franchina T, Ricciardi GRR, et al. The changing scenario of l(1)(q) line therapy in non-ocenogene addicted NSCLCs in the era of immunotherapy. Crit Rev Oncol Hematol, 2018, 130: 1-12. doi: 10.1016/j.critrevonc.2018.06.007

55 Sul J, Blumenthal GM, Jiang X, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. Oncologist, 2016, 21(5): 643-650. doi: 10.1634/theoncologist.2015-0498

56 Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med, 2018, 378(22): 2078-2092. doi: 10.1056/NEJMoa1801005

57 Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 2000, 18(1): 122-130. doi: 10.1200/JCO.2000.18.1.122

58 Reck M, Borghei H, O’Byrne KJ. Nivolumab plus ipilimumab in non-small-cell lung cancer: Future Oncol, 2019. doi: 10.2217/fon-2019-0031

59 Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer. J Clin Oncol, 2007, 25(33): 5233-5239. doi: 10.1200/JCO.2007.13.9030

60 Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2): 92-98. doi: 10.1056/NEJMoa011954

61 Adriaensen De A, Ashai N, Perez-Soler R, et al. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)0166. BMC Cancer, 2018, 18(1): 241. doi: 10.1186/s12885-018-4150-y

62 Pujol JL, Paz-Ares L, de Marinis F, et al. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care
immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer, 2014, 15(6): 418-425. doi: 10.1016/j.cllc.2014.06.007

64 Paz-Ares L, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol, 2013, 31(23): 2895-2902. doi: 10.1200/JCO.2012.47.1102

65 Scagliotti GV, Gridelli C, de Marinis F, et al. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. Lung Cancer, 2014, 85(3): 408-414. doi: 10.1016/j.jluncan.2014.07.005

66 Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet, 2016, 387(10026): 1415-1426. doi: 10.1016/S0140-6736(16)00004-0

67 Yu HA, Planchard D, Lovly CM. Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book, 2018(38): 726-739. doi: 10.1200/EDBK_201331

68 Remon J, Hendriks LE, Cabrera C, et al. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change? Cancer Treat Rev, 2018, 71: 47-58. doi: 10.1016/j.ctrv.2018.10.006

69 Hung WY, Chang JH, Cheng Y, et al. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities. Cell Physiol Biochem, 2018, 31(1): 337-355. doi: 10.1159/000495233

70 Lee DH, Lee JS, Wang J, et al. Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial. Cancer Res Treat, 2015, 47(4): 616-629. doi: 10.4143/crt.2014.051

71 Lee CK, Davies L, Wu YL, et al. Gefitinib or Erlotinib or Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. J Natl Cancer Inst, 2017, 109(6). doi: 10.1093/jnci/djw279

72 Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUUX-Lung 3 and LUUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol, 2015, 16(2): 141-151. doi: 10.1016/S1470-2045(14)71773-8

73 Paz-Ares L, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUUX-Lung 7 trial. Ann Oncol, 2017, 28(2): 270-277. doi: 10.1093/annonc/mdw611

74 Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 2018, 378(2): 113-125. doi: 10.1056/NEJMoa1713137

75 Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol, 2017, 18(11): 1454-1466. doi: 10.1016/S1470-2045(17)30608-3

76 Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol, 2018: JCO2018783118. doi: 10.1200/JCO.2018.78.3118

77 Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small cell lung cancer harbouring EGFR mutations (J025S67): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol, 2014, 15(11): 1236-1244. doi: 10.1016/S1470-2045(14)70381.X

78 Barata F, Queiroga H, Teixeira E, et al. MutAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC. EGF Mut. Rev. Rev Pneumol (2006), 2016, 22(5): 287-288. doi: 10.1016/j.rppnem.2016.03.009

79 Gridelli C, Rossi A, Ciardiello F, et al. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer, 2016, 17(5): 461-465. doi: 10.1016/j.jlcc.2016.04.001

80 Janne PA, Ou SH, Kim DW, et al. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol, 2014, 15(13): 1433-1441. doi: 10.1016/S1470-2045(14)70461-9

81 van Kruijsdijk RC, Visseren FL, Boni L, et al. Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction. Ann Oncol, 2016, 27(7): 1280-1286. doi: 10.1093/annonc/mdw154

82 Yoshimura N, Kudoh S, Mitsuoka S, et al. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation. Lung Cancer, 2015, 90(1): 65-70. doi: 10.1016/j.lungcan.2015.06.002

83 Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 2013, 368(25): 2385-2394. doi: 10.1056/NEJMoa1214886

84 Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med, 2014, 371(23): 2167-2177. doi: 10.1056/NEJMoa1408440

85 Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, 2017, 389(10072): 917-929. doi: 10.1016/S0140-6736(17)30123-X

86 Novello S, Mazieres J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol, 2018, 29(6): 1409-1416. doi: 10.1093/annonc/mdy121
87 Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol, 2017, 18(12): 1590-1599. doi: 10.1016/S1470-2045(17)30680-0

88 Jung D, Han JM, Yee J, et al. Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients. Med Oncol, 2018, 35(12): 154. doi: 10.1007/s12032-018-1213-5

89 Spagnuolo A, Maione P, Gridelli C. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first-to third-generation of ALK inhibitors. Expert Opin Emerg Drugs, 2018, 23(3): 231-241. doi: 10.1080/14728224.2018.1527902

90 Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol, 2017, 18(10): 1307-1316. doi: 10.1016/S1470-2045(17)30679-4

91 Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med, 2015, 373(8): 726-736. doi: 10.1056/NEJMoa1503209

92 Goldman JW, Shi P, Reck M, et al. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. Clin Lung Cancer, 2016, 17(1): 80-84. doi: 10.1016/j.cllc.2015.08.003

93 Ellis PM, Leighl NB, Hirsh V, et al. A Randomized, Open-Label Phase II Trial of Visleterib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. Clin Lung Cancer, 2015, 16(6): 457-465. doi: 10.1016/j.cllc.2015.05.010

94 Heist RS, Wang X, Hodgson L, et al. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second line treatment of advanced non-small-cell lung cancer. J Thorac Oncol, 2014, 9(2): 214-221. doi: 10.1097/JTO.000000000000071

95 Paz-Ares LG, Perol M, Ciuleanu TE, et al. Treatment outcomes by histology in REVEL: A randomized phase III trial of ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer, 2017, 112: 126-133. doi: 10.1016/j.lungcan.2017.05.021

96 Reck M, Paz-Ares L, Bidoli P, et al. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer, 2017, 112: 181-187. doi: 10.1016/j.lungcan.2017.07.038

97 Soria JC, Fulop A, Maciel C, et al. SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol, 2017, 28(12): 3028-3036. doi: 10.1093/annonc/mdx628

98 Tanimura K, Uchino J, Tamiya N, et al. Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non-small cell lung cancer with brain metastasis. Medicine (Baltimore), 2018, 97(23): e11084. doi: 10.1097/MD.0000000000011084

99 Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017, 389(10066): 255-265. doi: 10.1016/S0140-6736(16)32517-X

100 Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced NonSquamous Non-Small-Cell Lung Cancer. N Engl J Med, 2015, 373(7): 1627-1639. doi: 10.1056/NEJMoa1507643

101 Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016, 387(10027): 1540-1550. doi: 10.1016/S0140-6736(15)01281-7

102 Lee CK, Man J, Lord S, et al. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol, 2018, 4(2): 210-216. doi: 10.1001/jamaoncol.2017.4427

103 Zhao Q, Xie R, Lin S, et al. Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic NonSquamous Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials. Biomed Res Int, 2018, 2018: 3820956. doi: 10.1155/2018/3820956

104 Hirano S, Naka G, Takeda Y, et al. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation. Chin Clin Oncol, 2016, 5(6): 77. doi: 10.21037/cco.2016.11.02

105 Uchino J, Nakao A, Tamiya N, et al. Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment. Medicine (Baltimore), 2018, 97(23): e11081. doi: 10.1097/MD.0000000000011081

106 Wang N, Wang L, Meng X, et al. Osimertinib (AZD9291) increases radiosensitivity in EGFR T790M non-small cell lung cancer. Oncol Rep, 2019, 41(1): 77-86. doi: 10.3892/or.2018.6803

107 Neal JW, Dahlberg SE, Wakelee HA, et al. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol, 2016, 17(12): 1661-1671. doi: 10.1016/S1470-2045(16)30561-7

108 az-Ares L, Hirsh V, Zhang L, et al. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients With Relapsed or Refractory Predominantly NonSquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. J Thorac Oncol, 2015, 10(12): 1745-1753. doi: 10.1097/JTO.0000000000000693

109 Sanchez L, Muchene L, Lorenzo-Luaces P, et al. Differential effects of two therapeutic cancer vaccines on short- and long-term survival populations among patients with advanced lung cancer. Semin Oncol, 2018, 45(1-2): 52-57. doi: 10.1053/j.semincancer.2018.04.005
《中国肺癌杂志》被CSCD（2021-2022年度）收录

2021年4月，《中国肺癌杂志》继续被中国科学引文数据库（Chinese Science Citation Database, CSCD）2021-2022年度收录为核心期刊（以C标记）。

CSCD创建于1989年，收录我国数学、物理、化学、天文学、地学、生物学、农林科学、医药卫生、工程技术、环境科学和管理科学等领域出版的中英文科技核心期刊和优秀期刊千余种，目前已积累从1989年到现在的论文记录5776880条，引文记录86132397条。

CSCD内容丰富、结构科学、数据准确。系统除具备一般的检索功能外，还提供新型的索引关系——引文索引，使用该功能，用户可迅速从数百万条引文中查询到某篇科技文献被引用的详细情况，还可以从一篇早期的重要文献或著者姓名入手，检索到一批近期发表的相关文献，对交叉学科和新学科的发展研究具有十分重要的参考价值。

CSCD还提供了数据链接机制，支持用户获取全文。

经过CSCD定量遴选、专家定性评估，2021-2022年度CSCD收录来源期刊1,262种，其中中国出版的英文期刊245种，中文期刊1,017种。CSCD来源期刊分为核心库和扩展库两部分，其中核心库926种（以备注栏中C为标记）；扩展库336种（以备注栏中E为标记）。

CSCD来源期刊每两年遴选一次。每次遴选均采用定量与定性相结合的方法，定量数据来自于CSCD，定性评价则通过聘请国内专家定性评估对期刊进行评审。定量与定性综合评估结果构成了CSCD来源期刊。